Overview

Applications

Our Abpromise guarantee covers the use of ab33470 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Sandwich ELISA 1/2000 - 1/4000. Can be paired for Sandwich ELISA with Rabbit monoclonal [EP1368Y] to Apolipoprotein A I (ab52945). PubMed: 20421239
WB Use a concentration of 1.5 µg/ml. Predicted molecular weight: 30 kDa.
ICC Use a concentration of 4 µg/ml.

Target

  • FunctionParticipates in the reverse transport of cholesterol from tissues to the liver for excretion by promoting cholesterol efflux from tissues and by acting as a cofactor for the lecithin cholesterol acyltransferase (LCAT). As part of the SPAP complex, activates spermatozoa motility.
  • Tissue specificityMajor protein of plasma HDL, also found in chylomicrons. Synthesized in the liver and small intestine.
  • Involvement in diseaseDefects in APOA1 are a cause of high density lipoprotein deficiency type 2 (HDLD2) [MIM:604091]; also known as familial hypoalphalipoproteinemia (FHA). Inheritance is autosomal dominant.
    Defects in APOA1 are a cause of the low HDL levels observed in high density lipoprotein deficiency type 1 (HDLD1) [MIM:205400]; also known as analphalipoproteinemia or Tangier disease (TGD). HDLD1 is a recessive disorder characterized by the absence of plasma HDL, accumulation of cholesteryl esters, premature coronary artery disease, hepatosplenomegaly, recurrent peripheral neuropathy and progressive muscle wasting and weakness. In HDLD1 patients, ApoA-I fails to associate with HDL probably because of the faulty conversion of pro-ApoA-I molecules into mature chains, either due to a defect in the converting enzyme activity or a specific structural defect in Tangier ApoA-I.
    Defects in APOA1 are the cause of amyloid polyneuropathy-nephropathy Iowa type (AMYLIOWA) [MIM:107680]; also known as amyloidosis van Allen type or familial amyloid polyneuropathy type III. AMYLIOWA is a hereditary generalized amyloidosis due to deposition of amyloid mainly constituted by apolipoprotein A1. The clinical picture is dominated by neuropathy in the early stages of the disease and nephropathy late in the course. Death is due in most cases to renal amyloidosis. Severe peptic ulcer disease can occurr in some and hearing loss is frequent. Cataracts is present in several, but vitreous opacities are not observed.
    Defects in APOA1 are a cause of amyloidosis type 8 (AMYL8) [MIM:105200]; also known as systemic non-neuropathic amyloidosis or Ostertag-type amyloidosis. AMYL8 is a hereditary generalized amyloidosis due to deposition of apolipoprotein A1, fibrinogen and lysozyme amyloids. Viscera are particularly affected. There is no involvement of the nervous system. Clinical features include renal amyloidosis resulting in nephrotic syndrome, arterial hypertension, hepatosplenomegaly, cholestasis, petechial skin rash.
  • Sequence similaritiesBelongs to the apolipoprotein A1/A4/E family.
  • Post-translational
    modifications
    Palmitoylated.
    Phosphorylation sites are present in the extracelllular medium.
  • Cellular localizationSecreted.
  • Information by UniProt
  • Database links
  • Alternative names
    • Apo AI antibody
    • Apo-AI antibody
    • ApoA I antibody
    • ApoA-I antibody
    • APOA1 antibody
    • APOA1/APOC3 fusion gene antibody
    • APOA1_HUMAN antibody
    • Apolipoprotein A I precursor antibody
    • Apolipoprotein A-I(1-242) antibody
    • Apolipoprotein A1 antibody
    • Apolipoprotein AI antibody
    • Apolipoprotein of high density lipoprotein antibody
    • ApolipoproteinAI antibody
    • Brp14 antibody
    • Ltw1 antibody
    • Lvtw1 antibody
    • MGC117399 antibody
    • Sep1 antibody
    • Sep2 antibody
    see all

References for Anti-Apolipoprotein A I antibody (ab33470)

This product has been referenced in:
  • Meriwether D  et al. Enhancement by LDL of transfer of L-4F and oxidized lipids to HDL in C57BL/6J mice and human plasma. J Lipid Res 52:1795-809 (2011). WB ; Human, Mouse . Read more (PubMed: 21804067) »
  • Park KH  et al. Senescence-related truncation and multimerization of apolipoprotein A-I in high-density lipoprotein with an elevated level of advanced glycated end products and cholesteryl ester transfer activity. J Gerontol A Biol Sci Med Sci 65:600-10 (2010). WB, Sandwich ELISA ; Human . Read more (PubMed: 20421239) »

See all 2 Publications for this product

Product Wall

Thank you for contacting us. Yes, the Apolipoprotein A I protein ab90760 is the correct target for the antibodies ab52945 and ab20918. However, please note that the only data we have for sELISA are : - ab52945 has been used in sELISA in pair wi...

Read More
Application Western blot
Sample Cow Cell lysate - whole cell (Smooth muscle cells)
Loading amount 30 µg
Specification Smooth muscle cells
Gel Running Conditions Reduced Denaturing (10)
Blocking step Milk as blocking agent for 30 minute(s) · Concentration: 5% · Temperature: RT°C
Username

Dr. GOSSELET Fabien

Verified customer

Submitted Apr 12 2011

Application Immunohistochemistry (Frozen sections)
Sample Mouse Tissue sections (Intestine)
Specification Intestine
Fixative 10% Formalin
Permeabilization Yes - 0.1% Triton X-100
Blocking step Serum as blocking agent for 30 minute(s) · Concentration: 10% · Temperature: 24°C
Username

Abcam user community

Verified customer

Submitted Oct 13 2010

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"